For maternal RSVPreF: Vaccine efficacy against RSV-positive severe medically-attended LRTI at 180 days after birth was 70 % (50.6, 82.5) and 49.2% (31.4, 62.8) against RSV-positive medically attended LRTI. Go to footnote 1
For nirsevimab: Efficacy against medically attended RSV-associated LRTI was 79% (68.5, 86.1). Efficacy against hospitalization for RSV-associated LRTI was 80.6% (62.3, 90.1) and efficacy against severe hospitalized RSV-associated LRTI was 78.5% (48.8,91.0). Both products have been shown to have high, similar effectiveness when used in real-world situations. Go to footnote 2, Go to footnote 3, Go to footnote 4
- Go back to footnote reference 1
Müller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. (2023). Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 388:1533–1534. doi:10.1056/NEJMc2214773.
- Go back to footnote reference 2
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. (2020). Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 383:415–425. doi:10.1056/NEJMoa1913556.
- Go back to footnote reference 3
Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. (2023). Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 388:1451–1464. doi:10.1056/NEJMoa2216480.
- Go back to footnote reference 4
Mallah N, Ares-Gómez S, Pardo-Seco J, Malvar-Pintos A, Santiago-Pérez MI, Pérez-Martínez O, et al. (2024). Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol. Hum Vaccin Immunother. 20(1):2348135. doi:10.1080/21645515.2024.2348135.
